Dusica Cvetkovic

Dr. Dusica Cvetkovic

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2012 in Physics in Medicine & Biology
Verified
Journal Article
Open access
ZMZhaomei Mu
Zhaomei Mu
CMC-M Ma
C-M Ma
XCXiaoming Chen
Xiaoming Chen
DCDusica Cvetkovic
Dusica Cvetkovic
APAlan Pollack
Alan Pollack
LCLili Chen
Lili Chen
The purpose of this study is to evaluate the efficacy of the enhancement of docetaxel by pulsed focused ultrasound (pFUS) in combination with radiotherapy (RT) for treatment of prostate cancer in vivo. LNCaP cells were grown in the prostates of male nude mice. When the tumors reached a designated volume by MRI, tumor bearing mice were randomly divided into seven groups (n = 5): (1) pFUS alone; (2) RT alone; (3) docetaxel alone; (4) docetaxel + pFUS; (5) docetaxel + RT; (6) docetaxel + pFUS + RT, and (7) control. MR-guided pFUS treatment was performed using a focused ultrasound treatment system (InSightec ExAblate 2000) with a 1.5T GE MR scanner. Animals were treated once with pFUS, docetaxel, RT or their combinations. Docetaxel was given by i.v. injection at 5 mg kg(-1) before pFUS. RT was given 2 Gy after pFUS. Animals were euthanized 4 weeks after treatment. Tumor volumes were measured on MRI at 1 and 4 weeks post-treatment. Results showed that triple combination therapies of docetaxel, pFUS and RT provided the most significant tumor growth inhibition among all groups, which may have potential for the treatment of prostate cancer due to an improved therapeutic ratio.

2 October 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
DRDiana Restifo
Diana Restifo
JMJoseph R. McDermott
Joseph R. McDermott
DCDusica Cvetkovic
Dusica Cvetkovic
TSTroy Dos Santos
Troy Dos Santos
COCharline Ogier
Charline Ogier
IAIgor Astsaturov
Igor Astsaturov
The greater efficacy of DNA-damaging drugs for pancreatic adenocarcinoma (PDAC) relies on targeting cancer-specific vulnerabilities while sparing normal organs and tissues due to their inherent toxicities. We tested LP-184, a novel acylfulvene analog, for its activity in preclinical models of PDAC carrying mutations in the DNA damage repair (DDR) pathways. Cytotoxicity of LP-184 is solely dependent on prostaglandin reductase 1 (PTGR1), so that PTGR1 expression robustly correlates with LP-184 cytotoxicity in vitro and in vivo. Low-passage patient-derived PDAC xenografts with DDR deficiencies treated ex vivo are more sensitive to LP-184 compared with DDR-proficient tumors. Additional in vivo testing of PDAC xenografts for their sensitivity to LP-184 demonstrates marked tumor growth inhibition in models harboring pathogenic mutations in ATR, BRCA1, and BRCA2. Depletion of PTGR1, however, completely abrogates the antitumor effect of LP-184. Testing combinatorial strategies for LP-184 aimed at deregulation of nucleotide excision repair proteins ERCC3 and ERCC4 established synergy. Our results provide valuable biomarkers for clinical testing of LP-184 in a large subset of genetically defined characterized refractory carcinomas. High PTGR1 expression and deleterious DDR mutations are present in approximately one third of PDAC making these patients ideal candidates for clinical trials of LP-184.

19 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SAShahabeddin M Aslmarand
Shahabeddin M Aslmarand
TSTroy Dos Santos
Troy Dos Santos
DYDae-Myoung Yang
Dae-Myoung Yang
DCDusica Cvetkovic
Dusica Cvetkovic
LCLili Chen
Lili Chen
Chang Ming Charlie MaChang Ming Charlie Ma
Chang Ming Charlie Ma
Purpose: Pulsed low dose rate radiotherapy (PLDR) is a radiotherapy approach expected to reduce normal tissue toxicity while maintaining equivalent tumor control as conventional radiotherapy (CRT). This preliminary study evaluates the effectiveness of PLDR in reducing normal tissue toxicity in vivo. Materials and Methods: In the initial phase, C57BL/6 mice underwent histological examination following single-fraction, total-body irradiation. Observations were conducted at 3 and 5 days post-treatment. Mice were divided into control, PLDR, and CRT groups, receiving varying doses ranging from 4 to 12 Gy. Building upon the histological findings, the second phase centered on whole-abdominal irradiation (WAI) and determining the lethal dose for WAI using CRT. Subsequently, this dose was applied in PLDR settings to compare survival rates and changes in body weight. The experiment was replicated to collect histology samples at 1-, 3-, 5-, 7-, and 9-day endpoints, enabling the assessment and comparison of tissue toxicity. Finally, exploration into PLDR’s lethal WAI dose was conducted. Results: Histology results showed the abdominal region as the main site of difference between PLDR and CRT, with both methods causing a dose-dependent increase in atrophy and hyperplasia. However, CRT led to higher tissue toxicity compared to PLDR. In the survival study, the fatal dose for WAI treatment was 18 Gy, with mice in the CRT group experiencing substantial weight loss and dying within 9–12 days post-treatment. In contrast, mice in the PLDR group, despite an initial weight loss, recovered their weight and survived. Histology results also showed that the PLDR group had less tissue toxicity. Furthermore, the fatal dose of WAI for PLDR was revealed to be 29 Gy, which is over 60% higher than the dose required for CRT, indicating a substantial difference in tolerance and potential safety margin provided by PLDR treatment. Conclusions: PLDR demonstrated a reduced normal toxicity compared to CRT, potentially beneficial in re-treatment scenarios or for tumors where CRT-induced toxicity limits tumor control, such as in liver cases.

1 January 2008 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
DCDusica Cvetkovic
Dusica Cvetkovic
SWStephen J. Williams
Stephen J. Williams
Precancer is a very early noninvasive lesion that has genetic abnormalities, loss of cellular control functions, some phenotypic characteristics of invasive cancer, and predicts a significant likelihood of developing invasive cancer. Currently, there is no consensus on the existence of ovarian cancer precursor lesions, though many dysplasias in the ovary have been found to date. Our inability to detect precancer in the ovary has hampered early detection efforts. After review of current literature, inclusion cysts, deep surface invaginations and papillomatosis, commonly referred to as “putative ovarian precancer lesions” appear to correlate with known genetic alterations found in the advanced disease in predisposed cohorts. Although we suggest that screening for these lesions would underestimate the ovarian cancer risk in general population, data on chemoprevention studies offers new hope for combating this deadly disease.


27 November 2025
Verified
Other
Open access
DRDiana Restifo
Diana Restifo
JMJoseph R. McDermott
Joseph R. McDermott
DCDusica Cvetkovic
Dusica Cvetkovic
TSTroy Dos Santos
Troy Dos Santos
COCharline Ogier
Charline Ogier
IAIgor Astsaturov
Igor Astsaturov
Supplementary Table 2 from Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies